Zenas Biopharma Inc (ZBIO)

$21.01 +0.35 (1.69%)
Market Cap 1.11B
Revenue (ttm) 5.00M
Net Income (ttm) -156.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,139.80%
Debt to Equity Ratio 0.00
Volume 941,300
Avg Vol 782,712
Day's Range N/A - N/A
Shares Out 53.68M
Stochastic %K 67%
Beta -1.50
Analysts Strong Sell
Price Target $40.75

Company Profile

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal anti...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 271 2954
Address:
852 Winter Street, Suite 250, Waltham, United States
JFais
JFais Feb. 4 at 8:54 PM
$ZBIO CEO $1M purchase
0 · Reply
staydowngetdown
staydowngetdown Feb. 4 at 8:00 PM
$ZBIO 💎 $AQST $TNXP
0 · Reply
PepCF
PepCF Feb. 4 at 3:21 PM
$ZBIO back to 40
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 4 at 3:19 PM
$ZBIO
0 · Reply
MarketAtlas
MarketAtlas Feb. 4 at 2:29 PM
$ZBIO is an actively managed ETF focused on biotechnology; its performance is tied to the biotech sector, which is volatile and driven by clinical trial news.
0 · Reply
staydowngetdown
staydowngetdown Feb. 4 at 12:54 PM
$ZBIO
0 · Reply
Benalish
Benalish Feb. 4 at 3:05 AM
$ZBIO interesting - very unusual for a ceo to buy so much… I’ve seen it go both ways - sometimes the stock is under valued other times the stock keeps dropping anyways so just watch their cash levels. $ALT ceo bought shares then they did a capital raise a few weeks later
2 · Reply
outlawinvestor1
outlawinvestor1 Feb. 4 at 2:22 AM
$ZBIO another $1M ceo buy. leon is no fool.
0 · Reply
staydowngetdown
staydowngetdown Feb. 3 at 11:36 PM
$ZBIO 👀
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 7:19 PM
$ZBIO RSI: 43.83, MACD: -3.1226 Vol: 2.08, MA20: 19.19, MA50: 30.52 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on ZBIO
Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Feb 4, 2026, 7:05 AM EST - 1 day ago

Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 14 days ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 16, 2026, 4:15 PM EST - 20 days ago

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript

Jan 6, 2026, 2:58 PM EST - 4 weeks ago

Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript

Why Zenas BioPharma's Selloff Was Structurally Inevitable

Jan 6, 2026, 7:38 AM EST - 4 weeks ago

Why Zenas BioPharma's Selloff Was Structurally Inevitable

Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor

Jan 6, 2026, 4:58 AM EST - 4 weeks ago

Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor

Zenas BioPharma Touts Phase 3 Win, But Stock Crashes

Jan 5, 2026, 10:21 AM EST - 4 weeks ago

Zenas BioPharma Touts Phase 3 Win, But Stock Crashes

Zenas BioPharma's immune disorder drug meets main goal in late-stage trial

Jan 5, 2026, 8:29 AM EST - 4 weeks ago

Zenas BioPharma's immune disorder drug meets main goal in late-stage trial

Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Jan 5, 2026, 7:05 AM EST - 4 weeks ago

Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 19, 2025, 4:15 PM EST - 6 weeks ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus

Dec 15, 2025, 7:05 AM EST - 7 weeks ago

Zenas BioPharma's Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus

Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating

Dec 15, 2025, 4:18 AM EST - 7 weeks ago

Zenas Prepares For INDIGO Phase 3 Readout - Reinstating Buy Rating

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025, 7:05 AM EST - 3 months ago

Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

Nov 11, 2025, 7:05 AM EST - 3 months ago

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

Oct 27, 2025, 7:05 AM EDT - 3 months ago

Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis

Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal

Oct 9, 2025, 8:00 AM EDT - 4 months ago

Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal

Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug

Oct 8, 2025, 6:04 AM EDT - 4 months ago

Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

Oct 8, 2025, 5:00 AM EDT - 4 months ago

Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

Sep 2, 2025, 7:05 AM EDT - 5 months ago

Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

RPRX

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Aug 12, 2025, 7:05 AM EDT - 6 months ago

Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

Jul 28, 2025, 1:42 PM EDT - 6 months ago

Zenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MS

FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

Jun 16, 2025, 3:44 AM EDT - 8 months ago

FINAL ALERT NOTICE - ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Jun 15, 2025, 10:44 AM EDT - 8 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Jun 12, 2025, 6:17 PM EDT - 8 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

Jun 11, 2025, 10:24 AM EDT - 8 months ago

ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

May 31, 2025, 8:55 AM EDT - 8 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma

Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

May 29, 2025, 7:05 AM EDT - 9 months ago

Zenas BioPharma to Present at the Jefferies Global Healthcare Conference

JFais
JFais Feb. 4 at 8:54 PM
$ZBIO CEO $1M purchase
0 · Reply
staydowngetdown
staydowngetdown Feb. 4 at 8:00 PM
$ZBIO 💎 $AQST $TNXP
0 · Reply
PepCF
PepCF Feb. 4 at 3:21 PM
$ZBIO back to 40
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Feb. 4 at 3:19 PM
$ZBIO
0 · Reply
MarketAtlas
MarketAtlas Feb. 4 at 2:29 PM
$ZBIO is an actively managed ETF focused on biotechnology; its performance is tied to the biotech sector, which is volatile and driven by clinical trial news.
0 · Reply
staydowngetdown
staydowngetdown Feb. 4 at 12:54 PM
$ZBIO
0 · Reply
Benalish
Benalish Feb. 4 at 3:05 AM
$ZBIO interesting - very unusual for a ceo to buy so much… I’ve seen it go both ways - sometimes the stock is under valued other times the stock keeps dropping anyways so just watch their cash levels. $ALT ceo bought shares then they did a capital raise a few weeks later
2 · Reply
outlawinvestor1
outlawinvestor1 Feb. 4 at 2:22 AM
$ZBIO another $1M ceo buy. leon is no fool.
0 · Reply
staydowngetdown
staydowngetdown Feb. 3 at 11:36 PM
$ZBIO 👀
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 2 at 7:19 PM
$ZBIO RSI: 43.83, MACD: -3.1226 Vol: 2.08, MA20: 19.19, MA50: 30.52 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
knobs101
knobs101 Jan. 29 at 3:14 PM
$ZBIO looking like a nice bounce coming. Let's stretch that green candlestick.
0 · Reply
Trader1141
Trader1141 Jan. 29 at 12:12 PM
$SGMT good news and goong into the red.. lmao $ZBIO $GRI $DRUG
0 · Reply
outlawinvestor1
outlawinvestor1 Jan. 28 at 8:43 PM
$ZBIO it will continue to go higher.
0 · Reply
Trader1141
Trader1141 Jan. 28 at 7:47 PM
$GRI remonds me of $ZBIO tanked after good news from 30 to 10… bakc up to 20 😎
1 · Reply
MaxDanger
MaxDanger Jan. 26 at 7:44 PM
$ZBIO what’s the bull case for this drug? The efficacy data isn’t as strong as the competition. The safety seems great though. Is that what they are banking on? I just started learning about this company so excuse any obvious questions that the veterans of this board know well.
2 · Reply
Trader1141
Trader1141 Jan. 22 at 3:24 PM
$GLSI this will be another $ZBIO … dropped 50% on good news… eventually came back. I would wait to buy
0 · Reply
Smurfologist
Smurfologist Jan. 21 at 2:55 PM
$ZBIO Black Ski Mask Banditos, MOUNT UP!!! SMASH AND GRAB THIS STOCK TIL DA BULLS COME HOME; WHO YOU WID?!? 🙏🏾💪🏾🐃💣💥🚀
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 21 at 12:17 AM
$ZBIO Share Price: $20.89 Contract Selected: Aug 21, 2026 $20 Calls Buy Zone: $4.25 – $5.25 Target Zone: $6.84 – $8.35 Potential Upside: 52% ROI Time to Expiration: 212 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Smurfologist
Smurfologist Jan. 20 at 5:51 AM
$ZBIO I am so looking forward to this short week of trading. This stock is making me sleep with my Black Ski Mask on so I can participate in the joy of finding a stock that has great potential to grow. It is a great set up for, say it with me now.......SMASH AND GRAB ALL WEEK LONG; WHO YOU WID!!! 🙏🏾💪🏾🐃💣💥🚀
0 · Reply
PepCF
PepCF Jan. 19 at 3:26 PM
$ZBIO I’m sidelined for now since I was in RZLT and BHVN. Looking to entry this week sub-20 to play the gap fill. Beyond the CEO's heavy buying, they’ve got 13 job postings live—clearly hiring for the commercial rollout. Maybe it lacks a 'whale' like Baker Bros right now, but I expect the price to be way up from here soon
0 · Reply
Smurfologist
Smurfologist Jan. 16 at 8:28 PM
$ZBIO Finish strong in the last half hour!! 🙏🏾💪🏾🐃💣💥🚀
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Jan. 16 at 4:56 PM
$ZBIO Any other catalyst this year? Trying to initiate a position here. That was a disappointing P3, since it did not beat the currently approved Amgen treatment. I see that it has a better safety profile, though. Not sure that is enough for doctors to switch. Longer term, I like the pipeline, though. Would it be safe to wait till 2027?
0 · Reply